Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure.

Fiche du document

Auteurs
Date

2021

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2021.639235

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34804911

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2234-943X

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_029DBD20C8A64

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/

Mots-clés 0

HCC; TACE; hepatocellular carcinoma; longitudinal data analysis; portal hypertension; transarterial chemoembolization; variceal bleeding

Sujets proches En

PVP Ethenylpyrrolidinonehomopolymer Polyvinylpyrrolidone Polyvidon

Citer ce document

C. Frangakis et al., « Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure. », Serveur académique Lausannois, ID : 10.3389/fonc.2021.639235

Métriques

Partage / Export

Résumé 0

Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension. Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) group (n=57); liver metastasis group (n=42)] who underwent 279TACEs and had longitudinal pre-/post-therapy contrast-enhanced-MRI (n=388) and complete blood work were included. Outcomes of interest were platelet count (PC), spleen volume, ascites and portosystemic collaterals. Variables included TACE type/number, tumor type, microcatheter location, Child-Pugh, baseline tumor burden (tumor number/total/largest size), vessel invasion, alpha-fetoprotein, Eastern Cooperative Oncology Group (ECOG) performance status, and Model for End-Stage Liver Disease (MELD) score. Generalized Estimating Equations assessed the associations between TACE and outcomes. Power analysis determined the sample size was sufficient. No significant change in PC over time was observed in either groups, regardless of liver function (P>0.05). Baseline spleen volume was 226 cm 3 for metastatic group, and was larger by 204 cm 3 for HCC group (P

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en